BIO Bio-Rad Laboratories Inc

  1. Stocks
  2. Healthcare
  3. NYSE: BIO

Price (delayed)

$379

Market cap

$11.22B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.5

Enterprise value

$12.14B

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, ...

Highlights
The EPS has plunged by 139% YoY but it has soared by 95% from the previous quarter
The net income has shrunk by 109% YoY but it has soared by 95% QoQ
Bio-Rad Laboratories's gross profit has decreased by 7% YoY and by 2.6% from the previous quarter
The revenue has contracted by 4% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.bio-rad.com/
Peers: TMO BDX HBIO A

Key stats

What are the main financial stats of BIO
Market
Shares outstanding
29.61M
Market cap
$11.22B
Enterprise value
$12.14B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
4.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.37
Earnings
Revenue
$2.78B
EBIT
-$202.02M
EBITDA
-$202.02M
Free cash flow
$126.8M
Per share
EPS
-$6.5
Free cash flow per share
$4.28
Book value per share
$329.9
Revenue per share
$93.9
TBVPS
$436.95
Balance sheet
Total assets
$13.67B
Total liabilities
$3.9B
Debt
$1.38B
Equity
$9.76B
Working capital
$2.69B
Liquidity
Debt to equity
0.14
Current ratio
5.56
Quick ratio
3.99
Net debt/EBITDA
-4.54
Margins
EBITDA margin
-7.3%
Gross margin
54.9%
Net margin
-6.8%
Operating margin
14.4%
Efficiency
Return on assets
-1.5%
Return on equity
-2.1%
Return on invested capital
-1.6%
Return on capital employed
-1.5%
Return on sales
-7.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time
Intraday
1.62%
1 week
-0.82%
1 month
-13.07%
1 year
-27.46%
YTD
-9.87%
QTD
-20.88%

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.78B
Gross profit
$1.53B
Operating income
$401.11M
Net income
-$188.96M
Gross margin
54.9%
Net margin
-6.8%
The net margin has dropped by 119% year-on-year but it has surged by 95% since the previous quarter
The net income has shrunk by 109% YoY but it has soared by 95% QoQ
BIO's operating income is down by 27% year-on-year and by 17% since the previous quarter
BIO's operating margin is down by 24% year-on-year and by 16% since the previous quarter

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
BIO P/E details
P/E
N/A
P/B
1.15
P/S
4.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.37
The EPS has plunged by 139% YoY but it has soared by 95% from the previous quarter
BIO's P/B is 32% below its 5-year quarterly average of 1.7 and 23% below its last 4 quarters average of 1.5
The equity has contracted by 4.1% YoY
The stock's price to sales (P/S) is 22% less than its 5-year quarterly average of 5.2 and 16% less than its last 4 quarters average of 4.8
The revenue has contracted by 4% YoY

Efficiency

How efficient is Bio-Rad Laboratories business performance
Bio-Rad Laboratories's ROA has plunged by 200% YoY but it has soared by 95% from the previous quarter
The ROE has dropped by 200% year-on-year but it has soared by 95% since the previous quarter
The ROS has soared by 96% from the previous quarter
The company's return on invested capital has surged by 96% QoQ but it fell by 14% YoY

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The company's current ratio rose by 9% YoY
BIO's total liabilities is down by 7% year-on-year
The debt is 86% smaller than the equity
The equity has contracted by 4.1% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.